Effects of antirheumatic agents on cytokines

Seminars in Arthritis and Rheumatism

Volumn 25, Issue 4, 1996, Pages 234-253

  Barrera, P ^a   Boerbooms, A M T ^a   Van De Putte, L B A ^a   Van Der Meer, J W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; GOLD; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

EID: 0029872644     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(96)80035-7     Document Type: Article

References (187)

1. Edmonds J.P. Scott D.L. Furst D.E. Antirheumatic drugs: A proposed new classification Arthritis Rheum 36 1993 336 339
2. Arend W.P. Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis Arthritis Rheum 38 1995 151 160
3. Van de Loo F.A.J. Joosten L.A.B. van Lent P.L.E.M. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situblocking in murine antigen- and zymosan-induced arthritis Arthritis Rheum 38 1995 164 172
4. Dinarello C.A. Interleukin-1 and interleukin-1 antagonism Blood 77 1991 1627 1652
5. Collotta F. Dower S.K. Sims J.E. The type II ‘decoy’ receptor: a novel regulatory pathway for interleukin 1 Immunol Today 15 1994 562 566
6. Cope A.P. Maini R.N. Soluble tumor necrosis factor receptors in arthritis J Rheumatol 22 1995 382 384
7. Koch A.E. Kunkel S.L. Stricter R.M. Cytokines in rheumatoid arthritis J Invest Med 43 1995 28 38
8. Tilg H. Trehu E. Atkins M.B. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptorp55 Blood 83 1994 113 118
9. Firestein G.S. Xu W. Townsend K. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophagecolony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid arthritis J Exp Med 168 1988 1573 1586
10. Firestein G.S. Zvaifler N.J. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. Low levels of synovial fluid and synovial tissue interferon suggest that gamma interferon is not, the primary macrophage activating factor Arthritis Rheum 30 1987 864 871
11. Simon A.K. Seipelt E. Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis Proc Natl Acad Sci USA 91 1995 8562 8566
12. Zurawski G. de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells but not on T cells Immunology Today 15 1994 19 26
13. Waldmann T.A. The IL-2/IL-2 receptor system: a target for rational immunointervention Immunology Today 14 1993 264 270
14. Weinblatt M.E. Biological agents in rheumatoid arthritis J Rheumatol 19 suppl 32 1992 84 88
15. Rubin L.A. Nelson D.L. The soluble interleukin-2 receptor: biology, function and clinical application Ann Int Med 113 1990 619 627
16. Dinarello C.A. Modalities for reducing interleukin 1 activity in disease Immunol Today 14 1993 260 264
17. Arner E.C. Darnell L.R. Pratta M.A. Effect of antiinflammatory drugs on human interleukin-1 induced cartilage degradation Agents Actions 21 1987 334 336
18. Sperber K. Quraishi H. Kalb T.H. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-a) and IL-6 in human monocytes and T cells J Rheumatol 20 1993 803 808
19. Danis V.A. Franic G.M. Brooks P.M. The effect of slow-acting anti-rheumatic drugs (SAARDs) and combination of SAARDs on monokine production in vitro Drugs Exp Clin Res 17 1991 549 554
20. Deleuran B. Kristensen M. Paludan K. The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells Cytokine 4 1992 403 409
21. Wallace D.J. Linker-Israeli M. Metzger A.L. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE Lupus 2 suppl 1 1993 13 15
22. Wallace D.J. Linker-Israeli M. Hyun S. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic Inpus erythematosus (letter) J Rheumatol 21 1994 375 376
23. Rordorf Adam C. Lazdins J. Woods Cook K. An assay for the detection of interleukin-1 synthesis inhibitors: effects of antirheumatic drugs Drugs Exp Clin Res 15 1989 355 362
24. Picot S. Peyron F. Donadille A. Chloroquineinduced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism Immunology 80 1993 127 133
25. Landewe R.B. Miltenburg A.M. Breedveld F.C. Cyclosporin and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derivedfrom a patient with rheumatoid arthritis J Rheumatol 19 1992 1353 1357
26. Connolly K.M. Stecher V.J. Danis E. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs Agents Actions 25 1988 94 105
27. Ertel W. Morrison M.H. Ayala A. Chloroquine attenuates haemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II expression through blockade of tumor necrosis factor and prostaglandin release Blood 78 1991 1781 1788
28. Drakes M.L. Harth M. Galsworthy S.B. Effects of gold on the production of and response to human interleukin-1 J Rheumatol 14 1987 1123 1127
29. Remvig L. Enk C. Bligaard N. Effect of auranofin and sodium aurothiomalate on interleukin-1 production from human monocytes in vitro Scand J Rheumatol 17 1988 255 262
30. Okamoto M. Sasano M. Goto M. Suppressive effect of anti-rheumatic drugs on interleukin-1β release from human peripheral blood monocytes Int J Immunopharmac 13 1991 39 43
31. Danis V.A. Kulesz A.J. Nelson D.S. The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation inhealthy subjects and patients with arthritis Clin Exp Immunol 79 1990 335 340
32. Awad M. Corrigall V.M. Dayer J.M. Effects of gold salts on monocytes maturation and their pattern of cytokine secretion Br J Rheumatol 34 suppl 1 1995 288
33. Chang D.M. Baptiste P. Schur P.H. The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes J Rheumatol 17 1990 1148 1157
34. Williams D.H. Jeffery L.J. Murray E.J. Aurothioglu cose inhibits induced NF-kp and AP-1 activity by acting as an IL-1 functional antagonist Biochim Biophys Acta 1180 1992 9 14
35. Lee J.C. Dimartino M.J. Votta B.J. Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritis rats J Immunol 139 1987 3268 3274
36. Danis V.A. Kulesz A.J. Kelly D.E. The effect of gold treatment on monocyte interleukin-1 production in rheumatoid arthritis. A prospective study Rheumatol Int 10 1990 153 158
37. Shingu M. Fujikawa Y. Wada T. Increased IL-1 receptor antagonist (IL-Ira) production and decreased IL-lβ/IL-lra ratio in mononuclear cells from rheumatoid arthritis patients Br J Rheumatol 34 1994 24 30
38. Loetscher P. Dewald B. Baggiolini M. Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs Cytokine 6 1994 162 170
39. Seitz M. Dewald B. Ceska M. Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, andeffects of gold sodium thiomalate and methotrexate Rheumatol Int 12 1992 159 164
40. Evans G.F. Zuckerman S.H. Pharmacologic modulation of TNF production by endotoxin stimulated macrophages: in vitro and in vivo effects of auranofin and othercrysotherapeutic compounds Agents Actions 26 1989 329 334
41. Pichangkul S. Shick D. Jia F.L. Binding of tumor necrosis factor alpha (TNF-alpha) to high affinity receptors on polymorphonuclear cells Exp Hematol 15 1987 1055 1059
42. Ritcher J. Effect of auranofin on cytokine induced secretion of granule proteins from adherent human neutrophils in vitro Ann Rheum Dis 50 1990 372 375
43. Madhok R. Crilly A. Murphy E. Gold therapy lowers serum interleukin 6 levels in rheumatoid arthritis J Rheumatol 20 1993 630 633
44. Dasgupta B. Corkill M. Kirkham B. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis J Rheumatol 19 1992 22 25
45. Crilly A. Madhok R. Watson J. Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second line drug therapy Br J Rheumatol 33 1994 821 825
46. Yanni G. Nabil M. Farahat M.R. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane Ann Rheum Dis 53 1994 315 322
47. Hamilton J.A. Rheumatoid arthritis: opposing actions of haematopoietic growth factors and slow-acting antirheumatic drugs Lancet 342 1993 536 5339
48. Hashimoto K. Whitehurst C.E. Lipsky P.E. Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin J Rheumatol 21 1994 1020 1026
49. Sfikakis P.P. Souliotis V.L. Panayiotidis P.P. Suppression of interleukin-2 and interleukin-2 receptor biosynthesis by gold compounds in in vitro activated human peripheral blood mononuclearcells Arthritis Rheum 36 1993 208 212
50. Harth M. Cousin K. McCain G.A. Sodium aurothiomalate inhibits T cell responses to interleukin-2 Immunopharmacol Immunotoxicol 10 1988 141 156
51. Wolf R.E. Hall V.C. Inhibition of in vitro proliferation response of cultured T lymphocytes to interleukin-2 by gold sodium thiomalate Arthritis Rheum 31 1988 176 181
52. Vint A.M. Chain B.M. Foreman J.C. The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes Cell Immunol 152 1993 152 161
53. Harth M. Cousin K. McCain G.A. In vitro effects of two gold compounds, and D-penicillamine on the production of interferon gamma Immunopharmacol Immunotoxicol 12 1990 39 60
54. Moore N.C. Gough A. Emery P. Co-treatment with gold enhances IFN production by stimulated PBMNC in vitro Br J Rheumatol 29 suppl 2 1990 145
55. Sanders K.M. Carlson P.L. Littmann B.H. Effects of gold sodium thiomalate on interferon stimulation of C2 synthesis and HLA DR expression by human monocytes Arthritis Rheum 30 1987 1032 1039
56. Kawakami A. Eguchi K. Migita K. Inhibitory effects of gold sodium thiomalate on the proliferation and interferon-y induced HLA-DR expression in human endothelial cells J Rheumatol 17 1990 430 435
57. Newman P.N. To S.S.T. Robinson B.G. Effect of gold sodium thiomalate and its thiomalate component on the in vitro expression of endothelial cell adhesion molecules Arthritis Rheum 37 suppl 9 1994 S255 s2
58. Blitstein-Willinger E. Normalization of defective interleukin 1 and interleukin 2 production in patients with pemphigus vulgaris following chrysotherapy Clin Exp Immunol 62 1985 705 714
59. Kirkham B.W. Davison S.C. Corkill M.M. Serial soluble interleukin 2 receptor levels in rheumatoid arthritis: differences in response to glucocorticoid treatment and chrysotherapy J Rheumatol 20 1993 935 939
60. Sheldon A. Ahern M.J. Smith M.D. Response of soluble IL-2 receptor levels during gold therapy for rheumatoid arthritis Clin Exp Rheumatol 12 1994 175 178
61. Crilly A. Madhok R. Watson J. Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs Ann Rheum Dis 52 1993 58 60
62. Hirohata S. Lipsky P.E. Comparative inhibitory effects of bucillamine and D-penicillamine on the function of human B cells and T cells Arthritis Rheum 37 1994 942 950
63. Petersen J. Inhibition of T cell-dependent antibody production by D-penicillamine. Different requirements for Cu2+ in suppression of polyclonal andantigen-specific B cell responses Allergy 42 1987 37 45
64. Brisset M. Pujol J.P. Arenzana Seisdedos F. D-penicillamine inhibition of interleukin-1 production: a possible mechanism for its effect on synovial collagen synthesis? Int J Tissue React 8 1986 279 287
65. Martinez F. Coleman J.W. The effects of selected drugs, including chlorpromazine and non-steroidal antiinflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro Clin Exp Immunol 76 1989 252 257
66. DiMartino M.J. Johnson W.J. Votta B. Effect of antiarthritic drugs on the enhanced interleukin-1 (IL-1) production by macrophages from adjuvant-induced arthritic (AA) rats Agents Actions 21 1987 348 350
67. Teodorescu M. McAfee M. Skosey J.L. Covalent disulphide binding of human IL-1 beta to alpha 2-macroglobulin: inhibition by D-penicillamine Mol Immunol 28 1991 323 331
68. Lyle W.H. Penicillamine Clin Rheum Dis 5 1979 569 601
69. Matsubara T. Hirohata K. Suppression of human fibroblast proliferation by D-penicillamine and copper sulfate in vitro Arthritis Rheum 31 1988 964 972
70. Matsubara T. Saura R. Hirohata K. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine J Clin Invest 83 1989 158 167
71. Kashiwazaki S. Shiokawa Y. Bucillamine: a new immunomodulator Int J Immunother 3 1987 1 6
72. Hirohata S. Lipsky P.E. Regulation of B cell function by bucillamine, a novel disease modifying antirheumatic drug Clin Immunol Immunopathol 66 1993 43 51
73. Remvig L. Andersen B. Salicylazosulfapyridine (Salazopyrin) effect on endotoxin-induced production of interleukin-1-like factor from human monocytes in-vitro Scand J Rheumatol 19 1990 11 16
74. Grönberg A. Isaksson P. Smedegård G. Inhibitory effect of sulfasalazine on production of IL-1β, IL-6 and TNFα Arthritis Rheum 37 suppl 9 1994 S383
75. Malfait A.M. Verbruggen G. Almqvist K.F. Cytokine-cascade (IL-1, TNF-alpha, IL-6) in the co-culture of mononuclear cells and articular chondrocytes. Influence of sulphasalazine Clin Rheumatol 12 1993 41
76. Shanahan F. Niederlehner A. Carramanza N. Sulfasalazine inhibits the binding of TNFu to its receptor Immunopharmacology 20 1990 217 224
77. Danis V.A. Franic G.M. Rathjen D.A. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulfasalazine Ann Rheum Dis 51 1992 946 950
78. Barrera P. Boerbooms A.M.Th. Sauerwein R.W. Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity Lymphokine Cytokine Res 13 1994 155 159
79. Fujiwara M. Mitsui K. Ishida J. The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells Immunopharmacology 19 1990 15 21
80. Carlin G. Nymar A.K. Grönberg A. Effects of sulfasalazine on cytokine production by mitogen-stimulated human T-cells Arthritis Rheum 37 suppl 9 1994 S383
81. Lugmani R. Sheeran T. Robinson M. Systemic cytokine measurements: their role in monitoring the response to therapy in patients with rheumatoid arthritis Clin Exp Rheumatol 12 1994 503 508
82. Watson J. Crilly A. Madhok R. IL-6 and soluble IL-2 receptor in rheumatoid arthritis patients treated with second line drugs Biochem Soc Trans 20 1992 138S
83. Haagsma C.J. van Riel P.L.C.M. de Rooij D.J.R.A.M. Combination of methotrexate and sulfasalazine vs methotrexate alone: A randomized open clinical trial in rheumatoid arthritis patients resistant tosulfasalazine therapy Br J Rheumatol 33 1994 1049 1055
84. Barrera P. Haagsma C.J. Boerbooms A.M.Th. Effect of methotrexate alone or in combination with sulfasalazine on the production and circulating concentrations of cytokines and theirantagonists. Longitudinal evaluation in patients with rheumatoid arthritis Br J Rheumatol 34 1995 747 755
85. Segal R. Yaron M. Tartakowski B. Methotrexate: mechanism of action in rheumatoid arthritis Semin Arthritis Rheum 3 1990 190 199
86. Segal R. Mozes E. Yaron M. The effects of methotrexate on the production and activity of interleukin-1 Arthritis Rheum 32 1989 370 377
87. Segal R. Yaron M. Tartakowski B. Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system Arthritis Rheum 33 1990 1745 1749
88. Meyer F.A. Yaron I. Mashiah V. Methotrexate inhibits proliferation but not interleukin-1 stimulated secretory activities of cultured human synovial fibroblasts J Rheumatol 20 1993 238 242
89. Firestein G.S. Paine M.M. Boyle D.L. Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in collagenase gene expression Arthritis Rheum 37 1994 193 200
90. Miller L.C. Cohen E.E. Orencole S.F. Interleukin-1β (IL1β) is structurally related to dihydrofolate reductase: effects of methotrexate (MTX) on IL1 Cytokine Res 7 1988 1 49
91. Johnson W.J. DiMartino M.J. Meunier P.C. Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis J Rheumatol 15 1988 745 749
92. Hu S.K. Mitcho Y.L. Oronsky A.L. Studies on the effect of methotrexate on macrophage function J Rheumatol 15 1988 206 209
93. Kerwar S.S. Oronsky L. Methotrexate in rheumatoid arthritis: studies with animal models Adv Enzyme Regul 29 1989 247 265
94. Barrera P. Boerbooms A.M.Th. Demacker P.N.M. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dosemethotrexate Br J Rheumatol 33 1994 1017 1024
95. Chang D.M. Weinblatt M.E. Schur P.H. The effects of methotrexate on interleukin-1 in patients with rheumatoid arthritis J Rheumatol 19 1992 1678 1682
96. Kremer J.M. Petrillo G.F. Lawrence D.A. Methotrexate (MTX) induces significant changes in IL-1, IL-2, IL-6 and IL-8 but not lymphocyte markers in patients with rheumatoid arthritis (RA) Arthritis Rheum 36 1993 S77
97. Thomas R. Carroll G.J. Reduction of leukocyte and interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate Arthritis Rheum 36 9 1993 1244 1252
98. Barrera P. Boerbooms A.M.Th. Janssen E.M. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoidarthritis. Longitudinal evaluation during methotrexate and azathioprine therapy Arthritis Rheum 36 1993 1070 1079
99. Crilly A. McInness McDonald A.G. Interleukin-6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate J Rheumatol 22 1995 224 226
100. Nakarai T. Ueno Y. Ueno Y. Paradoxical enhancement of interleukin-2 mediated cytotoxicity against K562 cells by addition of a low dose of methotrexate Cancer Immunol Immunother 32 1990 8 12
101. Miller L.C. Dempsey R.D. Schaller J.G. Methotrexate (MTX) increases production of interleukin-2 (IL-2) Lymphokine Res 7 1988 7 35
102. Aaron S.L. Augmentation of IL-2 secretion by methotrexate therapy of rheumatoid arthritis Arthritis Rheum 32 1989 S50
103. Couret M. Combe B. Reme T. Production d'interleukine 2 et d'interferon-gamma dans la polyarthrite rhumatoïde au cours d'une étude longitudinale chez des patients traités par méthotrexate Revue Rhumatisme 57 1990 641 645
104. Kremer J.M. Lawrence D.A. Petrillo G.F. Immune effects of stopping and restarting methotrexate (MTX) in patients with rheumatoid arthritis Arthritis Rheum 37 suppl 9 1994 S252 s2
105. Flescher E. Bowlin T.L. Ballester A. Increased polyamines may down-regulate interleukin-2 production in rheumatoid arthritis J Clin Invest 83 1989 1356 1362
106. Nesher G. Osborn T. Moore T.L. Lymphocyte polyamine depletion in rheumatoid arthritis patients treated with methotrexate Arthritis Rheum 37 suppl 9 1994 S254 s2
107. Kremer J.M. The mechanism of action of methotrexate in rheumatoid arthritis. The search continues J Rheumatol 21 1994 1 5
108. Polisson R.P. Dooley M.A. Dawson D.V. Interleukin-2 receptor levels in the sera of rheumatoid arthritis patients treated with methotrexate Arthritis Rheum 37 1994 50 56
109. Rose C.D. Fawcett P.T. Gibney K. Serial measurements of soluble interleukin 2 receptor levels (sIL-2R) in children with juvenile rheumatoid arthritis treated with oral methotrexate Ann Rheum Dis 53 1994 471 474
110. Taylor R. Xie C. Beckenbaugh R. Disease specific lymphokine pattern in rheumatoid arthritis. Selective modulation by methotrexate Arthritis Rheum 37 suppl 9 1994 S277 s2
111. Kerstens P.J.S.M. Stolk J.N. Boerbooms A.M.T. Purine enzymes in rheumatoid arthritis. A clue to prediction of the response to azathioprine? Review and hypothesis Clin Exp Rheumatol 13 1995 107 111
112. Dupont E. Schandene L. Denys C. Differential in vitro actions of cyclosporin, methylprednisolone, and 6-mercaptopurine: implications for drugs' influence on lymphocyte activation mechanisms Clin Immunol Immunopathol 40 1986 422 428
113. Szawlowski P.W. Maddocks J.L. Effect of interleukin-2 on the inhibition of the human mixed lymphocyte reaction (MLR) by azathioprine Br J Clin Pharmacol 20 1985 107 110
114. Crilly A. McInnes I.B. Capell H.A. The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor Scand J Rheumatol 23 1994 87 91
115. Jain J. McCaffrey P.G. Miner Z. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun Nature 365 1993 352 355
116. Russell R.G.G. Graveley R. Coxon F. Cyclosporin A. Mode of action and effects on bone and joint tissues Scand J Rheumatol 21 suppl 95 1992 9 18
117. Goldfeld A.E. Tsai E. Kincaid R. Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells J Exp Med 180 1994 763 768
118. Andersson J. Nagy S. Groth C.G. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single cell level Immunology 75 1992 136 142
119. Yocum D.E. Wilder R.L. Dougherty S. Immunologic parameters of response in patients with rheumatoid arthritis treated with cyclosporin A Arthritis Rheum 33 1990 1310 1316
120. Crilly A. Kolta S. Dougados M. Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis Ann Rheum Dis 54 1995 137 139
121. Falkenbach A. Wigand R. Unkelbach U. Cyclosporin treatment in rheumatoid arthritis is associated with an increased serum activity of beta-glucuronidase Scand J Rheumatol 22 1993 83 85
122. Brynskov J. Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin Gut 31 1990 795 799
123. Clements P.J. Lanchenbruch P.A. Sterz M. Cyclosporin in systemic sclerosis. Results of a forty-eightweek open safety study in ten patients Arthritis Rheum 36 1993 75 83
124. Schlagheke R. Beusner D. Kornely E. Effects of glucocorticoids in rheumatoid arthritis. Diminished glucocorticoid receptors do not result in glucocorticoid resistance Arthritis Rheum 37 1994 1127 1131
125. Lee S.W. Tsou A.P. Chan H. Glucocorticoids selectively inhibit the transcription of the interleukin 1β gene and decrease the stability of interleukin 1β mRNA Proc Natl Acad Sci USA 85 1988 1204 1208
126. Amano Y. Lee S.W. Allison A.C. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability Mol Pharmacol 43 1993 176 182
127. Shaw G. Kamen R. A conserved sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation Cell 46 1988 659 667
128. Kern J.A. Lamb R.J. Reed J.C. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms J Clin Invest 81 1988 237 244
129. Lee W. Oppenheim J.J. Matsushima K. Analysis of the suppression of IL-1α and IL-1β production on human peripheral mononuclear adherent cells by a glucocorticoid hormone J Immunol 140 1988 3034 3039
130. Beutler B. Krochin N. Milsark I.W. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance Science 232 1986 977 980
131. Waage A. Slupphaug G. Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts Eur J Immunol 20 1990 2439 2443
132. Mukaida N. Zachariae C.C.O. Gusella G.L. Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor J Immunol 146 1991 1212 1215
133. Reed S.C. Abide A.H. Alpers J.D. Effect of cyclosporin and dexamethasone on interleukin-2 receptor gene expression J Immunol 137 1986 150 154
134. Chikanza L.C. Panayi G.S. The effects of hydrocortisone on in vitro lymphocyte proliferation in corticosteroid sensitive and resistant subjects Eur J Clin Invest 23 1993 845 850
135. Akahoshi T. Oppenheim J.J. Matsushima K. Induction of high-affinity interleukin 1 receptor on human peripheral blood lymphocytes by glucocorticoid hormones J Exp Med 167 1988 924 936
136. Butler J.B. Huang X. Planck S.R. Discordant regulation of mRNA for IL-1β and its receptor by IL-1α and dexamethasone in cultured synoviocytes Arthritis Rheum 34 suppl 9 1991 S142
137. Snyers L. Wit L.D. Content J. Glucocorticoid upregulation of high affinity interleukin-6 receptors on human epithelial cells Proc Natl Acad Sci USA 87 1990 2838 2842
138. Hart P.H. Whitty G.A. Burgess D.R. Augmentation of glucocorticoid action on human monocytes by interleukin-4 Lymph Res 9 1990 147 153
139. Bendrups A. Hilton A. Meager A. Reduction of tumor necrosis factor a and interleukin-1β levels in human synovial tissue by interleukin-4 and glucocorticoid Rheumatol Int 12 1993 217 220
140. Vetto J.T. Papa M.Z. Lotze M.T. Reduction of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids J Clin Oncol 5 1987 496 503
141. Chatenoud L. Legendre C. Ferran C. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome. Dosage and kinetics prerequisites Transplantation 51 1991 334 338
142. Barber A.E. Coyle S.M. Marano M.A. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man J Immunol 150 1993 1992 2006
143. Robinson D. Hamid Q. Ying S. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5 and interferon-gammacytokine gene expression Am Rev Respir Dis 148 1993 401 406
144. Vecchiarelli A. Siracusa A. Cenci E. Effect of corticosteroid treatment on interleukin-1 and tumor necrosis factor secretion by monocytes from subjects with asthma Clin Exp Allergy 22 1992 365 370
145. Roche N.E. Fulbright J.W. Wagner A.D. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis Arthritis Rheum 36 1993 1286 1294
146. Van den Brink H.R. van Wijk M.J. Geertzen R.G. Influence of corticosteroid pulse therapy on the serum levels of soluble interleukin 2 receptor, interleukin 6 and interleukin 8 in patients withrheumatoid arthritis J Rheumatol 21 1994 430 434
147. Moachon L. Weill B.J. Chéreau C. Pulse methylprednisolone therapy reduces monocyte IL-1 production ex vivo (letter) J Rheumatol 16 1989 1515 1516
148. Wood N.C. Symons J.A. Dutz G.W. Serum interleukin-2 receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun 1 1988 353 361
149. Espersen G.T. Vestegaard M. Ernst E. Tumor necrosis factor alpha and interleukin-2 in plasma from rheumatoid arthritis patients in relation with disease activity Clin Rheumatol 10 1991 374 376
150. Gutierrez-Rodriguez O. Starusta-Bacal P. Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis. The thalidomide experience J Rheumatol 16 1989 158 163
151. Anaya J.M. Espinoza L.R. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases J Rheumatol 22 1995 595 599
152. Maksymowych W.P. Avina-Zubieta A. Luong M.H. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis J Rheumatol 22 1995 625 629
153. Dougados M. Combe B. Beveridge T. IX 207,887 in rheumatoid arthritis: A double-blind placebocontrolled study Arthritis Rheum 35 1992 999 1006
154. Sipe J.D. Bartle L.M. Loose L.D. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase response J Immunol 148 1992 480 484
155. Martel-Pelletier J. Ounissi H. Cloutier J.M. Tenidap effectively reduces cytokine synthesis and expression by human rheumatoid arthritis synovium Arthritis Rheum 37 suppl 9 1994 S309
156. Miltenburg A.M.M. Dolhain R.J.E.M. de Kuiper R. Tenidap inhibits T cell proliferation, cytokine production and the induction of mRNA encoding TNFα and IFN gamma Arthritis Rheum 37 suppl 9 1994 S384
157. Pelletier J.P. McCollum R. DiBattista J. Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs Arthritis Rheum 36 1993 1517 1527
158. 2 in vitro by mechanisms independent of inhibition of prostaglandin synthesis Arthritis Rheum 34 suppl 9 1991 D171
159. Lindsley H.B. Smith D.D. Cohick C.B. Suppression by tenidap of IFN-gamma-induced expression of HLA class II antigens on cultured human synoviocytes (HSC) and reduction of PBMNCadhesion to rheumatoid HSC in vitro J Immunol 150 1993 140A
160. Littman B.H. Drury C.E. Zimmerer R.O. Rheumatoid arthritis treated with tenidap and piroxicam. Clinical associations with cytokine modulation by tenidap Arthritis Rheum 38 1995 29 37
161. Leeming M.R.G. A double-blind randomised comparison of tenidap versus auranofin plus diclofenac in early rheumatoid arthritis Arthritis Rheum 36 suppl 9 1993 A84
162. Yocum D.E. The use of immunomodulators in early rheumatoid arthritis Semin Arthritis Rheum 23 suppl 2 1994 44 49
163. Pincus T. Callahan L.F. New therapeutic approaches in autoimmune rheumatic diseases, with special emphasis on rheumatoid arthritis Br J Rheumatol 34 1995 193 199
164. Cheung N.T. Taylor D. Dawes P.T. In vitro effect of leflunomide on RA synovial fibroblasts proliferation and production of the matrix metallo-proteinase pro-MMP3 Br J Rheumatol 34 suppl 1 1995 113
165. Mukaida N. Okamoto S. Ishikawa Y. Molecular mechanisms of interleukin-8 gene expression J Leukoc Biol 56 1994 554 558
166. Seitz M. Franke M. Kirchner H. Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma Ann Rheum Dis 47 1988 642 644
167. Graninger W.B. Hassfeld W. Pesau B.B. Induction of systemic lupus erythematosus by interferon-y in a patient with rheumatoid arthritis J Rheumatol 18 1991 1621 1622
168. Machold K.P. Smolen J.S. Interferon-γ induced exacerbation of systemic lupus erythematosus J Rheumatol 17 1990 831 832
169. Kahan A. Amor B. Menkes C.J. Recombinant interferon in the treatment of systemic sclerosis Am J Med 87 1989 273 277
170. Hein R. Behr J. Hündgen M. Treatment of systemic sclerosis with γ-interferon Br J Dermatol 126 1992 496 501
171. Vreugdenhil G. Schattenberg A. Dompeling E.C. Haemopoietic growth factors in rheumatoid arthritis: a critical approach to their use in view of possible adverse effects Am J Med 94 1993 229 230
172. Yasuda M. Kihara T. Wada T. Granulocyte colony-stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty's syndrome patient Arthritis Rheum 37 1994 145 146
173. Wijdenes J. Racadot E. Wendling D. Interleukin-6 antibodies in rheumatoid arthritis J Interferon Res 14 1994 297 298
174. Kyle V. Coughlan R.J. Tighe H. Beneficial effect of monoclonal antibody to interleukin-2 receptor on activated T cells in rheumatoid arthritis Ann Rheum Dis 48 1989 428 429
175. 486 IL-2 fusion toxin in refractory rheumatoid arthritis Arthritis Rheum 36 1993 1223 1233
176. 486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial withopen-label extension Arthritis Rheum 38 1995 1177 1186
177. 389IL-2 administered to patients with active rheumatoid arthritis (RA) receiving treatment with methotrexate(MTX) Arthritis Rheum 37 1994 S341
178. 389IL-2 administered up to four times a year to patients with active rheumatoid arthritis (RA) Arthritis Rheum 37 suppl 9 1994 S341
179. Lebsack M.E. Paul C.C. Bloedow D.C. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis Arthritis Rheum 34 1991 S45
180. Lebsack M.E. Paul C.C. Martindale J.J. A dose and regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis Arthritis Rheum 36 1993 S39
181. Drevlow B. Lovis R. Haag M.A. Phase I study of recombinant interleukin-1-receptor (rhu IL-1R) administered subcutaneously in patients with active rheumatoid arthritis Arthritis Rheum 37 suppl 9 1994 339
182. Elliott M.J. Maini R.N. Feldmann M. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a Arthritis Rheum 36 1993 1681 1690
183. Elliott M.J. Maini R.N. Feldmann M. Repeated therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with rheumatoid arthritis Lancet 344 1994 1125 1127
184. Elliott M.J. Maini R.N. Feldmann M. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
185. Elliott M.J. Woo P. Charles P. Treatment of systemic juvenile chronic arthritis (JCA) with monoclonal anti-TNFα. Temporary control of systemic but not articular features ofdisease Arthritis Rheum 37 suppl 9 1994 S276 s2
186. Rankin E.C.C. Choy E.H.S. Kassimos D. The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis Br J Rheumatol 34 1995 334 342
187. Moreland L.W. Margolies G.R. Heck L.W. Soluble tumor necrosis factor receptor (sTNFR): Results of a phase I dose-escalation study in patients with rheumatoid arthritis Arthritis Rheum 37 suppl 9 1994 S295 s2